Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Ex-Oppenheimer adviser to plead guilty in U.S. to insider trading

Published 2016-10-25, 04:06 p/m
© Reuters.  Ex-Oppenheimer adviser to plead guilty in U.S. to insider trading
PFE
-
RY
-

By Nate Raymond

NEW YORK, Oct 25 (Reuters) - A former investment adviser at an Oppenheimer Holdings Inc OPY.N unit plans to plead guilty on Tuesday to charges that he traded on inside information supplied by a childhood friend working at Pfizer Inc (NYSE:PFE) PFE.N , according to his lawyer.

David Hobson, 47, will plead guilty in Manhattan federal court to conspiracy and securities fraud charges over conduct prosecutors said began while he was at Royal Bank of Canada RY.TO unit RBC Capital Markets and then continued at Oppenheimer & Co Inc, Michael Bowers, his lawyer, said in an email.

Hobson, a Providence, Rhode Island, resident, would be the second individual to admit guilt in the case, after Michael Maciocio, Hobson's friend at Pfizer, pleaded guilty in May and reached a deal to cooperate with prosecutors.

The case was announced in June amid a resurgence of insider trading cases this year in Manhattan, where prosecutors have wrestled with a 2014 appellate ruling that limited the scope of insider trading laws.

According to prosecutors, Hobson and Maciocio engaged in an insider trading scheme from 2008 to 2014 based on information obtained by Maciocio, a director of chemical research and development at Pfizer.

In that job, Maciocio sometimes evaluated Pfizer's capacity to manufacture drugs being developed by other companies Pfizer considered potential acquisition targets or partners, authorities said.

While Maciocio was not typically given the identity of a company in a potential deal, with Hobson's help he performed research to discern its identity, the indictment said.

After identifying the company, Maciocio then passed the information to Hobson, his stockbroker, who executed trades in accounts belonging to himself, Maciocio, and clients of Oppenheimer and RBC, prosecutors said.

Trades by Hobson in the stocks of Medivation Inc, Ardea Biosciences Inc and Furiex Pharmaceuticals Inc resulted in profits of $180,000 for himself, $40,000 for Maciocio and $150,000 for certain of Hobson's clients, prosecutors said.

The case is U.S. v. Hobson, U.S. District Court, Southern District of New York, No. 16-cr-351.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.